Design and Rationale of ARMADA-AD Disease Registry: An International, Prospective, Observational Registry to Characterize Unmet Needs and Evaluate Real-World Effectiveness and Safety of Systemic Therapies in Adults and Adolescents with Atopic Dermatitis
Main Article Content
Keywords
ARMADA-AD , Systemic Therapies, Atopic Dermatitis
Abstract
Introduction Despite recent advances in the management of atopic dermatitis (AD), patients continue to face significant burden and diminished quality of life1. Real-world studies are essential to understand patient needs and evaluate long-term effectiveness and safety of current therapies. Here, we present the design of ARMADA-AD disease registry that aims to collect real-world data to characterize unmet needs in AD, patient journey, and long-term outcomes of various AD treatment options.
Procedure/Study ARMADA-AD, a global, multicenter, longitudinal, prospective, observational, real-world study, plans to recruit atleast 1000 patients aged ≥12 years with confirmed diagnosis of AD and follow them for 5 years. Patients initiating or switching a systemic therapy for AD (including, but not limited to biologics, oral JAKi, and immunosuppressive/immunomodulatory therapies) will be included. Patients concurrently participating in interventional clinical trials will be excluded. Primary objectives are to comprehensively document patients’ unmet needs, describe patient characteristics and treatment patterns, and characterize real-world safety, effectiveness, and patient satisfaction with systemic treatment options for AD. Key secondary objectives include evaluation of longitudinal course of AD and selected atopic and non-atopic comorbidities, long-term safety and effectiveness of systemic AD therapies, impact of AD treatment across relevant sub-groups, general healthcare practices, and comprehensive patient experiences.
Results ARMADA-AD is expected to begin enrollment in H1 2025.
Conclusion Data collected from the ARMADA-AD registry will address existing gaps and serve as a valuable resource to further our understanding of unmet needs and burden of AD, and real-world safety and effectiveness of systemic therapies, compared to other registries.
References
2. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21-40. doi:10.1038/s41573-021-00266-6.
3.Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65-S76. doi:10.1016/j.jaci.2017.01.011.
4. Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8 Suppl):S115-S123.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.